With your own knowledge and the help of the following document:

Document 1 (Title: Genetic Determinants of Lipoprotein Metabolism and Vascular Disease): High-density lipoprotein cholesterol (HDL-C) represents a complex, heterogeneous lipoprotein fraction historically associated with cardioprotective effects, though the causal nature of this relationship has been increasingly questioned. While epidemiological studies consistently demonstrate inverse associations between HDL-C levels and cardiovascular disease (CVD) risk, genetic studies and therapeutic trials targeting HDL-C have yielded inconsistent results, suggesting more complex relationships than initially proposed. Mutations causing low HDL-C occur through various mechanisms, predominantly affecting apolipoprotein A-I (the principal HDL protein component), ATP-binding cassette transporter A1 (ABCA1, mediating cellular cholesterol efflux), lecithin-cholesterol acyltransferase (LCAT, catalyzing cholesterol esterification), or cholesteryl ester transfer protein (CETP, facilitating lipid exchange between lipoproteins). These genetic variants produce distinct HDL particle compositions beyond simply reduced cholesterol content, potentially explaining divergent clinical manifestations. Surprisingly, detailed phenotypic characterization of subjects with genetically determined low HDL-C has not consistently demonstrated the accelerated atherosclerosis predicted by epidemiological associations. Particularly compelling evidence comes from studies of ABCA1 mutation carriers (Tangier disease), who despite profoundly reduced HDL-C levels, demonstrate only modestly increased cardiovascular risk. Similarly, LCAT deficiency, while producing dramatic HDL reduction, shows inconsistent associations with premature atherosclerosis. Even apoA-I mutations, affecting the structural protein of HDL, demonstrate variable vascular phenotypes not consistently correlating with HDL-C reduction magnitude. Contemporary mechanistic research suggests HDL functionality—its capacity to promote reverse cholesterol transport, exert anti-inflammatory effects, and maintain endothelial function—may be more relevant to cardiovascular protection than absolute HDL-C concentration. This functionality appears partially independent of HDL-C levels, explaining apparent discrepancies between epidemiological associations and genetic studies. Subclinical atherosclerosis assessment through carotid intima-media thickness (cIMT) measurement has been particularly informative, with multiple studies specifically examining the relationship between genetically determined low HDL-C and vascular structure. These investigations consistently demonstrate that isolated genetic causes of low HDL-C without accompanying metabolic perturbations do not significantly increase cIMT compared to controls, contradicting predictions based solely on HDL-C levels. This dissociation between HDL-C concentration and vascular phenotype has profound implications for therapeutic approaches targeting HDL, suggesting intervention efficacy may depend on functional improvements rather than simple quantitative HDL-C elevation.
Document 2 (Title: Epidemiology of Atherosclerotic Cardiovascular Disease): Coronary artery disease continues to represent a leading cause of morbidity and mortality worldwide, with extensive epidemiological research identifying multiple modifiable and non-modifiable risk factors contributing to its development. Tobacco exposure, particularly cigarette smoking, consistently demonstrates among the strongest modifiable risk associations, with large cohort studies documenting 2-4 fold increased relative risk in current smokers compared to never-smokers, alongside dose-dependent relationships with cumulative exposure. Lipoprotein abnormalities play central roles in atherogenesis, with elevated apolipoprotein B concentrations representing a particularly strong predictor of coronary risk regardless of corresponding LDL-cholesterol levels. This relationship reflects apolipoprotein B's presence on all atherogenic lipoprotein particles, providing superior risk prediction compared to traditional lipid measurements in multiple prospective studies. Elevated blood pressure constitutes another firmly established risk factor, with each 20 mmHg systolic or 10 mmHg diastolic increase associated with approximately doubling of cardiovascular mortality across the entire blood pressure range starting from 115/75 mmHg. More recently, lipoprotein(a) has emerged as an independent risk factor, with elevated plasma levels conferring significantly increased coronary risk through both atherogenic and prothrombotic mechanisms resistant to conventional lipid-lowering approaches. Protective factors have also been identified, with high-density lipoprotein (HDL) demonstrating inverse association with coronary risk, reflecting its crucial role in reverse cholesterol transport and various anti-inflammatory functions. However, recent intervention trials targeting HDL have emphasized that its relationship with coronary disease appears more complex than initially conceptualized, with functional characteristics potentially more important than absolute concentration measurements. These collective findings inform current risk assessment algorithms and targeted intervention strategies for primary and secondary coronary disease prevention.
Document 3 (Title: Fundamentals of Single-Gene Metabolic Diseases): Phenylketonuria (PKU) represents a paradigmatic inborn error of metabolism caused by mutations in the phenylalanine hydroxylase (PAH) gene, resulting in deficient conversion of phenylalanine to tyrosine. The condition exemplifies several fundamental genetic principles that govern monogenic disorders. While variable expressivity describes differing phenotypic severity among individuals with the same mutation, anticipation refers to progressively earlier onset or increasing severity across generations, a phenomenon not observed in most metabolic disorders. Multiple gene mutations, though responsible for some complex traits, do not explain the diverse manifestations of PKU, which result from a single gene defect. Rather, pleiotropy—the phenomenon where a single gene produces multiple, seemingly unrelated phenotypic effects—explains the constellation of clinical features. In PKU, elevated phenylalanine and its metabolites act through numerous biochemical pathways to produce apparently disparate manifestations: hypophenylalaninemia causes hypopigmentation through reduced melanin synthesis; neurotoxic effects of phenylalanine and its metabolites lead to intellectual disability, seizures, and microcephaly; competitive inhibition of amino acid transporters results in abnormal protein synthesis; and characteristic musty odor derives from phenylacetic acid excretion. The multisystem effects all trace back to the primary biochemical defect, demonstrating how one gene affects multiple phenotypic features through interconnected pathways. Early diagnosis through newborn screening permits dietary intervention before irreversible neurological damage occurs, though treatment burden and compliance challenges remain substantial throughout the lifespan.

Answer the following true/false question.
Question: Do mutations causing low HDL-C promote increased carotid intima-media thickness?
Options:
A. True
B. False

Please respond **only** with a single valid JSON object in the following format:
{"answer": "True"}  ← if the answer is true
{"answer": "False"} ← if the answer is false
Do not include any other text or comments. Output must be strictly JSON.